AgingResearch.NewsJoin free
Immunity & Ageing

Drug pair restores saliva flow in mice modeling Sjögren’s disease

An experiment with six female mice per group tested dasatinib and quercetin, which reduced immune-cell buildup in salivary glands.

Paper by Yingliang Shi, Yi Guo, Hanlin Tu, +6 more authorsGuoliang Sa · Wuhan University
Figure 1 from Immunity & Ageing
Open the figure at full size
Figure 1. Shi et al.

Our read

Interventions
Studied:
Experiments in mice (Randomized, dose-response)
In the record:
One of 335 papers on Dasatinib + quercetin on record: 55 with results in people, 182 in animals.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Ten-week-old female non-obese diabetic mice, used to model primary Sjögren’s disease, were randomly assigned to three groups in an animal experiment, with six mice per group. They received dasatinib plus quercetin, a drug-free vehicle or no intervention. Sjögren’s is an autoimmune disease affecting salivary glands.

The drug combination cleared senescent cells—cells that stop dividing—and restored saliva flow after two treatment courses compared with both control groups. It also reduced immune-cell buildup in the glands. Human salivary-gland samples from female donors showed an accumulation of senescent fibroblasts, cells that support tissue structure, compared with healthy controls. Experiments in human salivary-gland fibroblasts grown in the lab identified a protein pathway associated with senescence and greater recruitment of CD4 T cells, a type of immune cell.

Why it matters

Advancing age is a risk factor for primary Sjögren’s disease. The authors suggest that clearing senescent cells may offer a strategy for reducing gland dysfunction.

Caveats

Drug effects were tested in a mouse disease model, not in people, and only female mice were studied. The abstract does not give the drug doses or total treatment duration.

Where the evidence stands

Dasatinib + quercetin

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 125 independent labs in 26 countries
  • 28 findings against
  • 18 trials, 1 with no results posted
  • Funders: National Institute on Aging and others
  • 79 of 683 findings with company ties
  • 1 of 18 trials sponsored by its developers

Cellular senescence

Cells, worms or flies, mice and humans: replicated by independent labs.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

Includes the processes named after it and trials of drugs aimed at it.

  • 865 independent labs in 75 countries
  • 521 findings against
  • 51 trials, 15 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 666 of 9,922 findings with company ties
  • 49 of 51 trials sponsored by developers of drugs aimed at it

Comments

Be the first to comment.

More on Cellular senescence